Literature DB >> 29722437

The opioid oxycodone use-dependently inhibits the cardiac sodium channel NaV 1.5.

Jannis E Meents1, Krisztina Juhasz2,3, Sonja Stölzle-Feix2, Vera Peuckmann-Post4, Roman Rolke4, Angelika Lampert1.   

Abstract

BACKGROUND AND
PURPOSE: Oxycodone is a potent semi-synthetic opioid that is commonly used for the treatment of severe acute and chronic pain. However, treatment with oxycodone can lead to cardiac electrical changes, such as long QT syndrome, potentially inducing sudden cardiac arrest. Here, we investigate whether the cardiac side effects of oxycodone can be explained by modulation of the cardiac Nav 1.5 sodium channel. EXPERIMENTAL APPROACH: Heterologously expressed human Nav 1.5, Nav 1.7 (HEK293 cells) or Nav 1.8 channels (mouse N1E-115 cells) were used for whole-cell patch-clamp electrophysiology. A variety of voltage-clamp protocols were used to test the effect of oxycodone on different channel gating modalities. Human stem cell-derived cardiomyocytes were used to measure the effect of oxycodone on cardiomyocyte beating. KEY
RESULTS: Oxycodone inhibited Nav 1.5 channels, concentration and use-dependently, with an IC50 of 483 μM. In addition, oxycodone slows recovery of Nav 1.5 channels from fast inactivation and increases slow inactivation. At high concentrations, these effects lead to a reduced beat rate in cardiomyocytes and to arrhythmia. In contrast, no such effects could be observed on Nav 1.7 or Nav 1.8 channels. CONCLUSIONS AND IMPLICATIONS: Oxycodone leads to an accumulation of Nav 1.5 channels in inactivated states, with a slow time course. Although the concentrations needed to elicit cardiac arrhythmias in vitro are relatively high, some patients under long-term treatment with oxycodone as well as drug abusers and addicts might suffer from severe cardiac side effects induced by the slowly developing effects of oxycodone on Nav 1.5 channels.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29722437      PMCID: PMC6016641          DOI: 10.1111/bph.14348

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures.

Authors:  Marcel Halbach; Ulrich Egert; Jürgen Hescheler; Kathrin Banach
Journal:  Cell Physiol Biochem       Date:  2003

2.  Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study.

Authors:  T I Saari; H Ihmsen; P J Neuvonen; K T Olkkola; H Schwilden
Journal:  Br J Anaesth       Date:  2011-12-26       Impact factor: 9.166

3.  Safety pharmacology studies using EFP and impedance.

Authors:  Alison Obergrussberger; Krisztina Juhasz; Ulrich Thomas; Sonja Stölzle-Feix; Nadine Becker; Leo Dörr; Matthias Beckler; Corina Bot; Michael George; Niels Fertig
Journal:  J Pharmacol Toxicol Methods       Date:  2016-04-12       Impact factor: 1.950

4.  Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.

Authors:  Alexander N Katchman; Kelly A McGroary; Michael J Kilborn; Craig A Kornick; Paolo L Manfredi; Raymond L Woosley; Steven N Ebert
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

5.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

Authors:  J W de Vos; P J Geerlings; W van den Brink; J G Ufkes; H van Wilgenburg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 6.  [Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression].

Authors:  K Güttler; R Sabatowski
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

7.  St John's wort greatly reduces the concentrations of oral oxycodone.

Authors:  Tuija H Nieminen; Nora M Hagelberg; Teijo I Saari; Mikko Neuvonen; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Pain       Date:  2010-01-27       Impact factor: 3.931

8.  Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a.

Authors:  Jennifer R Deuis; Zoltan Dekan; Joshua S Wingerd; Jennifer J Smith; Nehan R Munasinghe; Rebecca F Bhola; Wendy L Imlach; Volker Herzig; David A Armstrong; K Johan Rosengren; Frank Bosmans; Stephen G Waxman; Sulayman D Dib-Hajj; Pierre Escoubas; Michael S Minett; Macdonald J Christie; Glenn F King; Paul F Alewood; Richard J Lewis; John N Wood; Irina Vetter
Journal:  Sci Rep       Date:  2017-01-20       Impact factor: 4.379

9.  Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor.

Authors:  M Flinspach; Q Xu; A D Piekarz; R Fellows; R Hagan; A Gibbs; Y Liu; R A Neff; J Freedman; W A Eckert; M Zhou; R Bonesteel; M W Pennington; K A Eddinger; T L Yaksh; M Hunter; R V Swanson; A D Wickenden
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

View more
  1 in total

1.  Uncoupling sodium channel dimers restores the phenotype of a pain-linked Nav 1.7 channel mutation.

Authors:  Annika H Rühlmann; Jannis Körner; Ralf Hausmann; Nikolay Bebrivenski; Christian Neuhof; Silvia Detro-Dassen; Petra Hautvast; Carène A Benasolo; Jannis Meents; Jan-Philipp Machtens; Günther Schmalzing; Angelika Lampert
Journal:  Br J Pharmacol       Date:  2020-08-24       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.